Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

117.65 -0.95 (-0.80%)
Official Closing Price Updated: 4:10 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
40 41 Next >
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2022
Upgrades 
Via Benzinga
Earnings Season Is Here: Tesla, Netflix, IBM, AT&T And More On Deck - But This Stock Could Be 'Most Important'
The week of Oct. 17 is one of the busiest weeks for publicly traded companies reporting quarterly earnings. 
Via Benzinga
Expert Ratings for Abbott Laboratories
Abbott Laboratories (NYSE:ABT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
ABT INVESTOR NOTICE: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Abbott Laboratories Investors to Secure Counsel Before Important October 31 Deadline in Securities Class Action - ABT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Tesla Shares Have A Supporter in Congress: House Rep. McKinley Also Likes These 2 Dividend Stocks
Republican Congressman David McKinley recently purchased $1,000 to $15,000 shares in Tesla (NASDAQ: TSLA) for a price of $300.80 per share, in an undisclosed position, per Capito 
Via Benzinga
Friday Retreat: After Wild Thursday Rally, Market Stumbles into Weekend as Inflation Fears Grow
(Friday Market Close) More hints of rising inflation and worries about U.K. financial markets blew out the lights on Wall Street’s one-day party today. The benchmark S&P 500® (SPX) retreated toward... 
Via Benzinga
Abbott Says Recent Recall Of Some Bottles Of Infant Formula Will Not Hamper Supply
Via Benzinga
Analyst Ratings for Abbott Laboratories
Within the last quarter, Abbott Laboratories (NYSE:ABT) has observed the following analyst ratings: 
Via Benzinga
Where Abbott Laboratories Stands With Analysts
Within the last quarter, Abbott Laboratories (NYSE:ABT) has observed the following analyst ratings: 
Via Benzinga
3 Dividend Stocks to Buy Now for a Lifetime of Passive Income
These ultra-reliable businesses could deliver quarterly payments that steadily grow throughout your retirement. 
Via The Motley Fool
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Abbott, TuSimple, Kohl’s, and Bed Bath & Beyond and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off
All three of these medical stocks offer a high-yield dividend. 
Via The Motley Fool
3 Beaten-Down Stocks to Buy and Hold
These stocks could be ready for big bounces. 
Via The Motley Fool
Analyzing Abbott Laboratories's Short Interest
Abbott Laboratories's (NYSE:ABT) short percent of float has risen 23.68% since its last report. The company recently reported that it has 16.03 million shares sold short, which is 0.94% of all regular... 
Via Benzinga
Why the Bear Market May Not Be Over Anytime Soon
Are investors better off waiting until next year to buy stocks? 
Via The Motley Fool
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Abbott, TuSimple, Kohl’s, and Bed Bath & Beyond and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Expert Ratings for Abbott Laboratories
Over the past 3 months, 11 analysts have published their opinion on Abbott Laboratories (NYSE:ABT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding... 
Via Benzinga
Better Bear-Market Buy: Abbott Laboratories vs. AbbVie Stock
It's parent vs. child in this bear-market matchup. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
Upgrades 
Via Benzinga
3 Diabetes Care Stocks That Could Help Set You Up for Life
These companies are three of the leading manufacturers of continuous glucose monitoring systems. 
Via The Motley Fool
ROSEN, A LEADING LAW FIRM, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
2 Top Healthcare Stocks to Buy Right Now
Healthcare is about as sticky of a business model as you'll find. 
Via The Motley Fool
3 Great Dividend Stocks to Buy in October
Their dividends should be much bigger in the future. 
Via The Motley Fool
Why DexCom Stock Popped on Friday, Even as the Market Crumbled
The medical device maker could benefit from a pending decision by Medicare that could be a game changer. 
Via The Motley Fool
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Azure, Abbott, TuSimple, and Kohl’s and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Abbott Laboratories Whale Trades For October 06
A whale with a lot of money to spend has taken a noticeably bullish stance on Abbott Laboratories. Looking at options history for Abbott Laboratories (NYSE:ABT) we detected 10 strange trades. 
Via Benzinga
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Best Stocks 2022: What’s Not to Like About AbbVie (ABBV) Stock?
ABBV stock has rightly earned its place among the Best Stocks for 2022. This Dividend King is outperforming the S&P 500. 
Via InvestorPlace
$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today
Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 10 years by 1.74% on an annualized basis producing an average annual return of 11.68%. Currently, Abbott Laboratories has a... 
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Azure, Abbott, TuSimple, and Kohl’s and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
40 41 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.